GSK aims to shrink its consumer health PR roster; Merck accused of sunscreen overcharges; Bayer files for 4th Eylea use in EU;

> GlaxoSmithKline ($GSK) is reviewing its U.K. consumer health public relations accounts, aiming to cut down on the number of different agencies handling the products. Report

> Merck ($MRK) has been named in a proposed class-action suit claiming that the company overcharges for its Coppertone sunscreen products with SPFs of 55 and above, because they have "virtually identical" active ingredients as Coppertone products with a lower SPF. Report (reg. req.)

> Bayer asked European officials to approve a fourth indication for its injectable ophthalmology drug Eylea, as a treatment for visual impairment from macular edema caused by branch retinal vein occlusion. Report

> The physician drug compendium Epocrates topped the rankings of medical reference apps for smartphones for the fifth year in a row. Release

> AstraZeneca ($AZN) backed a series of videos to promote Mental Health America's latest awareness campaign. Report

> The FDA issued new guidance on distributing journal reprints, this time in relation to articles conveying new risk information. Report

> Sagent Pharmaceuticals made Crain's Chicago Business' list of fastest-growing companies in the region. Report

And Finally... AbbVie ($ABBV) unveiled results of a study of treatment adherence in patients with inflammatory disorders. Release

Suggested Articles

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.